My investment approach leans on statistical frameworks over emotional swings, like Bollinger Bands with 20,2 parameters (20-day mean, +/- 2 std deviations). 3
Questioning if a false breakout on $SPX nullifies current trendline/wedge/pennant patterns, hinting at nuanced interpretation. 7
$ALAB presents a clean setup: clear trendline, breakout retest, and teasing ATH VWAP. A clean break above VWAP is the tell for extreme bullishness. 9
$CIFR is mirroring a classic pattern (monthly breakout → retest) seen in $PLTR (Oct 2024), $HOOD (Apr 2025), $RKLB (Apr 2025), $ASTS (Sep ‘24 → May ‘25), $WULF (Sep 2025), $EOSE (Nov 2025), and $HUT (Nov 2025) right before their rallies. This pattern frequently precedes significant moves. 10
$NVDA holds a significant moat in the AI economy, controlling the full-stack AI compute layer from CUDA to Blackwell with over 90% market share. 4
Samsung and SK Hynix, dominating over 60% of the global NAND flash market, are strategically cutting production to maximize profits during a boom. 14
China is nearing High Bandwidth Memory (HBM) mass production through players like CXMT, focusing on building a resilient semiconductor equipment ecosystem. 16
Older memory chip prices (DDR4, DDR3 DRAM, NOR Flash, SLC/MLC NAND Flash) are expected to rally throughout 2026 as manufacturers shift focus to high-end AI data center chips, tightening older supply. 17
AI is set to significantly disrupt the software industry, creating both big winners and losers, with many popular software stocks potentially facing challenges. 15
Considering a YOLO play on $RYAAY, with the stock currently between $67 and $69, given Elon Musk’s recurring hints about a potential acquisition, reminiscent of $TWTR. 8
A new 40-page short report on $APP is making rounds, following previous critiques from Muddy Waters, Culpers, and Fuzzy Panda. Technicals also appear weak. 11
$INCY stands out as a “low beta + growth” pharma stock, offering defensive healthcare exposure without being a traditional stable play, despite early reliance on a single core drug. 13